Sesen Bio Reports First Quarter 2020 Financial Results and Meaningful Progress Towards Demonstrating Analytical Comparability By Andrew Clark, 11th May 2020
Sesen Bio Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium® By Andrew Clark, 7th May 2020
Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results By Andrew Clark, 16th March 2020
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium® By Andrew Clark, 25th February 2020
Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium® By Andrew Clark, 24th February 2020
